These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7809172)

  • 1. Pharmaceutical development of tablets of a new antineoplastic drug: mitonafide.
    Torres Suárez AI; Gil Alegre ME; Camacho Sánchez MA
    Pharm Acta Helv; 1994 Oct; 69(2):101-5. PubMed ID: 7809172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statistical method for evaluation of dissolution stability in the formulation development of solid dosage forms: tablets of amonafide.
    Gil-Alegre ME; Bernabeu JA; Camacho MA; Torres-Suarez AI
    Pharmazie; 2004 Jul; 59(7):541-7. PubMed ID: 15296092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Qualitative and quantitative determination of two new antitumor agents from 1-8 naphthalimides in tablets. Validation of a high performance liquid chromatography method.
    Camacho MA; Torres AI; Gil ME; Obregón MM; Ruz V
    Arzneimittelforschung; 1994 May; 44(5):659-62. PubMed ID: 8024643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of mitonafide in non-small cell lung cancer (NSCLC).
    Casado A; Rosell R; García-Gómez R; Díaz-Rubio E; Pérez-Manga G; Font A; Benavides A; Martín M
    Invest New Drugs; 1996; 14(4):415-7. PubMed ID: 9157079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statistical evaluation for stability studies under stress storage conditions.
    Gil-Alegre ME; Bernabeu JA; Camacho MA; Torres-Suarez AI
    Farmaco; 2001 Nov; 56(11):877-83. PubMed ID: 11765040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of mitonafide with a 3-day administration schedule: early interruption due to severe central nervous system toxicity.
    Díaz-Rubio E; Martín M; López-Vega JM; Casado A; Benavides A
    Invest New Drugs; 1994; 12(4):277-81. PubMed ID: 7775127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Photolability evaluation of the new cytostatic drug mitonafide.
    Torres Suárez AI; Camacho MA
    Arzneimittelforschung; 1994 Jan; 44(1):81-3. PubMed ID: 8135882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of mitonafide in solid tumors.
    Llombart M; Poveda A; Forner E; Fernández-Martos C; Gaspar C; Muñoz M; Olmos T; Ruiz A; Soriano V; Benavides A
    Invest New Drugs; 1992 Aug; 10(3):177-81. PubMed ID: 1428727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer.
    Rosell R; Carles J; Abad A; Ribelles N; Barnadas A; Benavides A; Martin M
    Invest New Drugs; 1992 Aug; 10(3):171-5. PubMed ID: 1330970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the performance of wet granulation and tablet hardness affect the drug dissolution profile of carvedilol in matrix tablets?
    Košir D; Ojsteršek T; Vrečer F
    Drug Dev Ind Pharm; 2018 Sep; 44(9):1543-1550. PubMed ID: 29848075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The performance of HPMC matrix tablets using various agglomeration manufacturing processes.
    Košir D; Vrečer F
    Drug Dev Ind Pharm; 2017 Feb; 43(2):329-337. PubMed ID: 27739880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Particle Engineering for Enabling a Formulation Platform Suitable for Manufacturing Low-Dose Tablets by Direct Compression.
    Sun WJ; Aburub A; Sun CC
    J Pharm Sci; 2017 Jul; 106(7):1772-1777. PubMed ID: 28322940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies about the oral bioavailability of mitonafide and 2HCl amonafide, two new cytotoxic molecules.
    Torres Suárez AI; Camacho Sánchez MA
    Farmaco; 1992 Apr; 47(4):497-508. PubMed ID: 1388597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of amonafide in central nervous system tumors: a Southwest Oncology Group study.
    Taylor SA; Rankin C; Townsend JJ; Craig JB; Vance RB; Solank DL; Brown TD; Jaeckle K;
    Invest New Drugs; 2002 Feb; 20(1):113-5. PubMed ID: 12003186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel, lean and environment-friendly granulation method: Green fluidized bed granulation (GFBG).
    Takasaki H; Sakurai A; Katayama T; Matsuura Y; Ohyagi N; Wada K; Ishikawa A; Yonemochi E
    Int J Pharm; 2019 Feb; 557():18-25. PubMed ID: 30572077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Particle Engineering of Excipients for Direct Compression: Understanding the Role of Material Properties.
    Mangal S; Meiser F; Morton D; Larson I
    Curr Pharm Des; 2015; 21(40):5877-89. PubMed ID: 26446468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of melt granulation technology to enhance tabletting properties of poorly compactible high-dose drugs.
    Lakshman JP; Kowalski J; Vasanthavada M; Tong WQ; Joshi YM; Serajuddin AT
    J Pharm Sci; 2011 Apr; 100(4):1553-65. PubMed ID: 24081475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel approach to support formulation design on twin screw wet granulation technology: Understanding the impact of overarching excipient properties on drug product quality attributes.
    Willecke N; Szepes A; Wunderlich M; Remon JP; Vervaet C; De Beer T
    Int J Pharm; 2018 Jul; 545(1-2):128-143. PubMed ID: 29684559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of silicified microcrystalline cellulose (Prosolv) as a polymer carrier of Epilobium parviflorum Schreb. extract in oral solid drug form.
    Marczyński Z; Zgoda MM; Jambor J
    Polim Med; 2007; 37(2):21-32. PubMed ID: 17957946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation and evaluation of dried yeast tablets using different techniques.
    Al-Mohizea AM; Ahmed MO; Al-jenoobi FI; Mahrous GM; Abdel-Rahman AA
    Eur J Pharm Biopharm; 2007 Aug; 67(1):253-9. PubMed ID: 17270410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.